Literature DB >> 19255916

The paraoxonases: role in human diseases and methodological difficulties in measurement.

Jordi Camps1, Judit Marsillach, Jorge Joven.   

Abstract

Research into the paraoxonase (PON) gene family has flourished over the past few years. In the 1970s and 1980s, only PON1 was known, and the investigations were conducted, essentially, by toxicologists focusing on protection against organophosphate poisoning. Since then, two new members of the family, PON2 and PON3, have been identified, both being shown to play antioxidant and anti-inflammatory roles. Evidence exists indicating that the PON family is central to a wide variety of human illnesses such as cardiovascular disease, diabetes mellitus, metabolic syndrome, obesity, non-alcoholic steatohepatitis, and several mental disorders. However, research is hampered considerably by the methods currently available to measure the activity of these enzymes. In this review, we summarize the state of knowledge on PON biochemistry and function, the influence of genetic variations, and the involvement of PON in several diseases. The problems associated with PON measurement, such as sample acquisition, lack of reference methods, and variety of substrates, will be presented. Also, we cover some of the present lines of research and propose some others for future progress in this field.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255916     DOI: 10.1080/10408360802610878

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  87 in total

1.  One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity.

Authors:  Sebastian Altenhöfer; Ines Witte; John F Teiber; Petra Wilgenbus; Andrea Pautz; Huige Li; Andreas Daiber; Heidrun Witan; Albrecht M Clement; Ulrich Förstermann; Sven Horke
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation.

Authors:  Gerard Aragonès; Anabel García-Heredia; Marta Guardiola; Anna Rull; Raúl Beltrán-Debón; Judit Marsillach; Carlos Alonso-Villaverde; Bharti Mackness; Michael Mackness; Juan Pedro-Botet; Pedro Pardo-Reche; Jorge Joven; Jordi Camps
Journal:  J Lipid Res       Date:  2011-10-14       Impact factor: 5.922

Review 3.  Paraoxonases as protective agents against N-acyl homoserine lactone - producing pathogenic microorganisms.

Authors:  Bogdan Nicolae Manolescu
Journal:  Maedica (Bucur)       Date:  2013-03

Review 4.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 5.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

Review 6.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.

Authors:  Lucio G Costa; Gennaro Giordano; Clement E Furlong
Journal:  Biochem Pharmacol       Date:  2010-11-18       Impact factor: 5.858

7.  Evaluation of oxidative stress status and antioxidant capacity in patients with painful bladder syndrome/interstitial cystitis: preliminary results of a randomised study.

Authors:  Kemal Ener; Murat Keske; Mustafa Aldemir; Muhammet Fuat Özcan; Emrah Okulu; Asım Özayar; Merve Ergin; Ömer Gökhan Doluoğlu; Serdar Çakmak; Özcan Erel
Journal:  Int Urol Nephrol       Date:  2015-06-07       Impact factor: 2.370

8.  Paraoxonase-1 and clopidogrel efficacy.

Authors:  Jordi Camps; Jorge Joven; Bharti Mackness; Michael Mackness; Dan Tawfik; Dragomir Draganov; Lucio G Costa; György Paragh; Ildikó Seres; Sven Horke; Richard James; Antonio Hernández; Srinivasa Reddy; Diana Shih; Mohamed Navab; Daniel Rochu; Michael Aviram
Journal:  Nat Med       Date:  2011-09-07       Impact factor: 53.440

9.  Association of PON1 gene polymorphisms with polycystic ovarian syndrome risk: a meta-analysis of case-control studies.

Authors:  D Liao; H Yu; L Han; C Zhong; X Ran; D Wang; L Mo
Journal:  J Endocrinol Invest       Date:  2018-03-15       Impact factor: 4.256

10.  Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.

Authors:  S A Pereira; J R Batuca; U Caixas; T Branco; J Delgado-Alves; I Germano; F Lampreia; E C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.